Smithfield Trust’s Biogen BIIB Stock Holding History

Smithfield Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37K	Buy	206 +200	+3,333%	+$36.9K	﹤0.01%	640
2025 Q4	$1K	Buy	+6	New	+$980	﹤0.01%	1063
2025 Q2	–	Sell	-100	Closed	-$14K	–	1040
2025 Q1	$14K	Sell	100 -4	-4%	-$572	﹤0.01%	797
2024 Q4	$16K	Hold	104	–	–	﹤0.01%	783
2024 Q3	$21K	Hold	104	–	–	﹤0.01%	713
2024 Q2	$25K	Hold	104	–	–	﹤0.01%	654
2024 Q1	$22K	Hold	104	–	–	﹤0.01%	694
2023 Q4	$27K	Hold	104	–	–	﹤0.01%	644
2023 Q3	$26K	Hold	104	–	–	﹤0.01%	642
2023 Q2	$30K	Hold	104	–	–	﹤0.01%	625
2023 Q1	$30K	Hold	104	–	–	﹤0.01%	598
2022 Q4	$30K	Sell	104 -8	-7%	-$2.26K	﹤0.01%	582
2022 Q3	$29K	Hold	112	–	–	﹤0.01%	582
2022 Q2	$23K	Hold	112	–	–	﹤0.01%	645
2022 Q1	$24K	Hold	112	–	–	﹤0.01%	661
2021 Q4	$27K	Hold	112	–	–	﹤0.01%	658
2021 Q3	$32K	Hold	112	–	–	﹤0.01%	628
2021 Q2	$39K	Hold	112	–	–	﹤0.01%	582
2021 Q1	$31K	Hold	112	–	–	﹤0.01%	625
2020 Q4	$27K	Sell	112 -22	-16%	-$5.67K	﹤0.01%	618
2020 Q3	$38K	Buy	134 +5	+4%	+$1.4K	﹤0.01%	545
2020 Q2	$35K	Buy	+129	New	+$38.8K	﹤0.01%	540
2019 Q4	–	Sell	-57	Closed	-$13K	–	950
2019 Q3	$13K	Hold	57	–	–	﹤0.01%	702
2019 Q2	$13K	Sell	57 -239	-81%	-$55.2K	﹤0.01%	683
2019 Q1	$70K	Buy	+296	New	+$93.2K	0.01%	449
2018 Q4	–	Sell	-300	Closed	-$106K	–	938
2018 Q3	$106K	Sell	300 -21	-7%	-$7.23K	0.01%	393
2018 Q2	$93K	Buy	321 +309	+2,575%	+$86.9K	0.01%	412
2018 Q1	$3K	Sell	12 -172	-93%	-$53.4K	﹤0.01%	905
2017 Q4	$58K	Buy	184 +101	+122%	+$32.4K	0.01%	509
2017 Q3	$26K	Buy	83 +43	+108%	+$12.7K	﹤0.01%	617
2017 Q2	$11K	Hold	40	–	–	﹤0.01%	705
2017 Q1	$11K	Hold	40	–	–	﹤0.01%	686
2016 Q4	$11K	Sell	40 -158	-80%	-$46.8K	﹤0.01%	679
2016 Q3	$62K	Hold	198	–	–	0.01%	473
2016 Q2	$48K	Hold	198	–	–	0.01%	489
2016 Q1	$51K	Hold	198	–	–	0.01%	480
2015 Q4	$60K	Hold	198	–	–	0.01%	462
2015 Q3	$58K	Hold	198	–	–	0.01%	466
2015 Q2	$80K	Sell	198 -362	-65%	-$145K	0.02%	429
2015 Q1	$236K	Buy	560 +28	+5%	+$11K	0.05%	280
2014 Q4	$180K	Hold	532	–	–	0.04%	327
2014 Q3	$176K	Sell	532 -339	-39%	-$112K	0.04%	328
2014 Q2	$274K	Hold	871	–	–	0.05%	258
2014 Q1	$267K	Sell	871 -319	-27%	-$101K	0.05%	272
2013 Q4	$332K	Buy	1,190 +21	+2%	+$5.43K	0.07%	231
2013 Q3	$282K	Buy	1,169 +669	+134%	+$150K	0.06%	248
2013 Q2	$108K	Buy	+500	New	+$107K	0.03%	396

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Smithfield Trust's BIIB Position: Q1 2026 in Review

Smithfield Trust increased its Biogen (BIIB) stake by 3,333% in Q1 2026, buying an estimated $36.9K and bringing the position to 206 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #640.

Smithfield Trust first reported a position in BIIB in Q2 2013 and has held it in 47 quarters since. The position peaked at $332K in Q4 2013. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Smithfield Trust held 206 shares of Biogen worth $37K as of Q1 2026.
Smithfield Trust bought 200 Biogen shares in Q1 2026, an estimated $36.9K.
Biogen made up ﹤0.01% of Smithfield Trust's portfolio in Q1 2026, its #640 holding.
Smithfield Trust first reported a position in Biogen in Q2 2013 and has held it in 47 quarters since.
Smithfield Trust's Biogen position peaked at $332K in Q4 2013.
1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.